Zhong N S, Chen R C, Yang M O, Wu Z Y, Zheng J P, Li Y F
Guangzhou Institute of Respiratory Disease, China.
Chest. 1992 Oct;102(4):1104-9. doi: 10.1378/chest.102.4.1104.
To determine the possibility that asymptomatic bronchial hyperresponsiveness (BHR) develops into symptomatic asthma, a two-year follow-up study was conducted in 81 students (48 male, 33 female; 11 to 17 years) who were found to have BHR in a 3,067 population survey (BHR group). Eighty-eight age-matched students (48 male, 40 female) with normal bronchial responsiveness served as control subjects. Daily symptom cards were recorded. Peak expiratory flow rate was measured for 24 h when symptoms occurred. Histamine inhalation tests were performed at the beginning of the study and at the end of the first and the second year. In the BHR group, 58 students remained bronchial hyperresponsive at the end of follow-up. Nine of 31 students with initially diagnosed bronchial asthma had their symptoms relieved entirely, but ten asymptomatic students developed asthma. The incidence of newly diagnosed asthma (12.5 percent in the BHR group or 20 percent in the asymptomatic BHR group) and the total percentage of diagnosed asthma (39.5 percent) in the BHR group were significantly higher than those (2.27 percent, 2.27 percent) in the control group. FVC and FEV1 showed no significant difference between two groups. PD20 FEV1 values in newly diagnosed asthmatics were significantly lower than those in asymptomatic students both at the beginning (3.05 +/- 1.56 mumol vs 6.14 +/- 1.60 mumol, p < 0.05) or the end (3.47 +/- 1.73 mumol vs 6.55 +/- 1.51 mumol, p < 0.05). The percentage of early respiratory illness was significantly higher in those with newly diagnosed asthma (80 percent) than in asymptomatic students (22.3 percent), but atopic index and the percentage of parental asthma showed no difference between two groups. In nine asthmatics whose symptoms were relieved entirely in the two-year follow-up, PD20 FEV1 was undetectable within the cumulative dose of 7.8 mumol of histamine in three students and rose from 4.58 +/- 1.85 mumol to 7.62 +/- 1.02 mumol in the remaining six. The higher the BHR, the more likely the students developed asthma. About 45 percent of asymptomatic students with PD20 < or = 3.2 mumol developed asthma in the following two years and 80 percent of them had a history of early respiratory illness, suggesting that they may have subclinical or potential asthma.
为了确定无症状支气管高反应性(BHR)发展为有症状哮喘的可能性,我们对在3067人的人群调查中发现有BHR的81名学生(48名男性,33名女性;年龄11至17岁)进行了一项为期两年的随访研究(BHR组)。88名年龄匹配、支气管反应性正常的学生(48名男性,40名女性)作为对照。记录每日症状卡。症状出现时测量24小时的呼气峰值流速。在研究开始时、第一年结束时和第二年结束时进行组胺吸入试验。在BHR组中,58名学生在随访结束时仍有支气管高反应性。最初诊断为支气管哮喘的31名学生中有9名症状完全缓解,但10名无症状学生发展为哮喘。BHR组新诊断哮喘的发生率(BHR组为12.5%,无症状BHR组为20%)和BHR组诊断哮喘的总百分比(39.5%)显著高于对照组(2.27%,2.27%)。两组间用力肺活量(FVC)和第一秒用力呼气容积(FEV1)无显著差异。新诊断哮喘患者的组胺激发剂量使FEV1下降20%(PD20 FEV1)值在开始时(3.05±1.56 μmol对6.14±1.60 μmol,p<0.05)和结束时(3.47±1.73 μmol对6.55±1.51 μmol,p<0.05)均显著低于无症状学生。新诊断哮喘患者的早期呼吸道疾病百分比(80%)显著高于无症状学生(22.3%),但特应性指数和父母哮喘百分比在两组间无差异。在两年随访中症状完全缓解的9名哮喘患者中,3名学生在累积组胺剂量7.8 μmol内未检测到PD20 FEV1,其余6名学生的PD20 FEV1从4.58±1.85 μmol升至7.62±1.02 μmol。BHR越高,学生发展为哮喘的可能性越大。PD₂₀≤3.2 μmol的无症状学生中约45%在接下来两年发展为哮喘,其中80%有早期呼吸道疾病史,提示他们可能有亚临床或潜在哮喘。